Blood Pressure MATTERS Act
- Sponsor
- Rep. Williams, Nikema [D-GA-5]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- May 7, 2026
Bottom line
The bill aims to improve maternal health outcomes by ensuring widespread, no-cost access to blood pressure monitoring devices for pregnant and postpartum individuals across all major insurance types.
What it actually does
This bill mandates that Medicaid, the Children's Health Insurance Program (CHIP), and private health insurance plans provide coverage for self-measured blood pressure monitoring devices for all pregnant and postpartum individuals. It prohibits cost-sharing for these devices and specifies that coverage must extend for 12 months postpartum, regardless of whether the individual has a hypertensive disorder, and limits coverage to one device every two years.
Proponents argue
Proponents argue that this bill is a crucial step to combat rising maternal mortality and morbidity rates, particularly those related to hypertensive disorders like preeclampsia and eclampsia. They emphasize that remote blood pressure monitoring facilitates early detection and intervention, which can save lives and reduce severe health complications, especially benefiting underserved populations and addressing health disparities.
Opponents contend
Potential opponents might express concerns about the increased financial burden on federal and state Medicaid/CHIP programs, as well as on private health insurance plans, which could lead to higher taxes or insurance premiums. They may also question the necessity of universal coverage for these devices without a prior diagnosis, suggesting it could result in over-utilization or strain healthcare resources.
The bill is concise and clearly written, allowing for a quick read and easy understanding of its core provisions.
Section 2(a)(1)
Mandatory Medicaid Coverage for Self-Measured Blood Pressure Monitoring
This provision amends Section 1905 of the Social Security Act to include 'self-measured blood pressure monitoring for pregnant and postpartum individuals' as a mandatory covered service under Medicaid. It defines this service to include a specified blood pressure measurement device furnished during pregnancy and for 12 months postpartum, without requiring a hypertensive disorder diagnosis, and limits coverage to one device per two-year period. The definition of a 'specified blood pressure management device' requires it to be FDA-cleared and listed on the American Medical Association's Validated Device Listing website.
Supporters argue
Proponents argue this ensures equitable access to a critical tool for managing and preventing hypertensive disorders, particularly for low-income individuals who may face significant barriers to care.
Critics contend
Opponents might argue that mandating coverage for all individuals, regardless of risk, could lead to unnecessary costs and potentially divert resources from higher-risk populations.
Tradeoffs
The provision balances universal access and preventative care against potential increases in program costs and the administrative burden on states.
Section 2(a)(2) and (3)
Prohibition of Medicaid Cost-Sharing and Mandatory State Coverage
These subsections further amend the Social Security Act to ensure that self-measured blood pressure monitoring is a mandatory benefit under state Medicaid plans and alternative benefit plans. Crucially, it explicitly prohibits states from imposing any cost-sharing requirements (such as copayments, deductibles, or premiums) for these devices for eligible individuals. This ensures that financial barriers to accessing the devices are completely removed.
Section 2(b)
Mandatory CHIP Coverage for Self-Measured Blood Pressure Monitoring
This section amends Section 2103(c) of the Social Security Act, requiring that any state CHIP plan that provides pregnancy-related assistance must include coverage for self-measured blood pressure monitoring. This ensures that low-income pregnant and postpartum women covered by CHIP receive the same access to these devices as those covered by Medicaid, aligning benefits across federal-state health programs.
Section 2(c)
Mandatory Private Health Insurance Coverage and No Cost-Sharing
This section amends the Public Health Service Act, the Employee Retirement Income Security Act of 1974 (ERISA), and the Internal Revenue Code of 1986. These amendments collectively require group health plans and health insurance issuers offering group or individual coverage to provide coverage for specified blood pressure management devices for pregnant and postpartum individuals. Similar to Medicaid, it prohibits cost-sharing for these devices and applies for the duration of pregnancy and 12 months postpartum, without requiring a hypertensive diagnosis, and limits coverage to one device per two-year period.
The bill limits coverage to 'not more than 1 such device furnished to an individual during a 2-year period.'
Section 2(a)(1)(B) and (ll)(1)(B)
Why it matters:This is standard legislative practice for defining the scope of a covered benefit, ensuring clarity on the frequency of device provision.
Case for: This limitation prevents excessive or redundant device provision, ensuring cost-effectiveness while still providing adequate monitoring for the specified period.
Case against: No specific opposition is typically raised against this type of limitation, as it is a common and reasonable aspect of benefit design.
Estimated impact: This limits the financial outlay for device provision to one per individual every two years, preventing continuous or multiple device purchases.
The bill defines 'specified blood pressure management device' as one that is FDA-cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act and is listed as a validated device on the Validated Device Listing website maintained by the American Medical Association.
Section 2(a)(1)(B) and (ll)(2)
Why it matters:This is standard legislative practice for ensuring the quality and efficacy of covered medical devices, relying on established regulatory and professional standards.
Case for: This ensures that only safe, effective, and clinically validated devices are covered, protecting patients and ensuring the utility of the mandate.
Case against: Some might argue that relying solely on the AMA's listing could potentially slow the adoption of innovative new devices if their validation process is lengthy, or limit consumer choice.
Estimated impact: This ensures quality control for covered devices but could influence market dynamics for manufacturers.
The effective date for Medicaid and CHIP amendments is 120 days after enactment, with an exception for states requiring legislative action. For such states, the effective date is extended to the first day of the first calendar quarter after the close of the first regular legislative session that begins after enactment.
Section 2(a)(4) and 2(b)(2)
Why it matters:This is a common and necessary legislative mechanism to provide states with adequate time to implement federal mandates, especially when state legislative processes are involved.
Case for: This flexibility ensures that states can comply with the new requirements without undue burden or disruption to existing programs, facilitating smoother implementation.
Case against: No specific opposition is typically raised against standard effective date clauses that account for state legislative cycles.
Estimated impact: This allows for staggered implementation across states, with some states implementing within 120 days and others taking longer, potentially up to two years for states with biennial legislative sessions.